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stem-like cells (BTSCs).[1,2] Tumor micro-
vasculature creates a complex microenvi-
ronment consisting of various cell types, 
the extracellular matrix, and soluble fac-
tors that mediate cell–cell interaction.[3] 
The brain tumor PVN controls mainte-
nance, expansion, and differentiation of 
BTSCs via direct cell contact or paracrine 
signaling cues.[4–6] BTSCs often receive 
bidirectional crosstalk from endothelial 
cells and other cell types in the niche.[7] 
In addition, the perivascular zone may 
serve as a path for tumor cells to migrate 
over long distances.[8,9] Unlike other 
solid tumors, glioblastoma multiforme 
(GBM) cells rarely metastasize to other 
organs, but they can invade the entire 
brain by migrating along specific brain 
tissue structures, such as blood vessels 
or white matter tracts, leading to high 
rates of relapse.[9–13] Despite the success 
in modeling diffuse brain tumors in both 
genetically modified and patient-derived 
xenograft (PDX) animals,[14] there is an 
unmet need for an in vitro system that can bridge conven-
tional cell culture and animal models by mimicking not only 
the anatomy but also the function of the PVN to study the 
dynamics of BTSCs.
The perivascular niche (PVN) plays an essential role in brain tumor stem-like 
cell (BTSC) fate control, tumor invasion, and therapeutic resistance. Here, a 
microvasculature-on-a-chip system as a PVN model is used to evaluate the 
ex vivo dynamics of BTSCs from ten glioblastoma patients. BTSCs are found 
to preferentially localize in the perivascular zone, where they exhibit either 
the lowest motility, as in quiescent cells, or the highest motility, as in the 
invasive phenotype, with migration over long distance. These results indicate 
that PVN is a niche for BTSCs, while the microvascular tracks may serve as 
a path for tumor cell migration. The degree of colocalization between tumor 
cells and microvessels varies significantly across patients. To validate these 
results, single-cell transcriptome sequencing (10 patients and 21 750 single 
cells in total) is performed to identify tumor cell subtypes. The colocaliza-
tion coefficient is found to positively correlate with proneural (stem-like) or 
mesenchymal (invasive) but not classical (proliferative) tumor cells. Further-
more, a gene signature profile including PDGFRA correlates strongly with 
the “homing” of tumor cells to the PVN. These findings demonstrate that the 
model can recapitulate in vivo tumor cell dynamics and heterogeneity, repre-
senting a new route to study patient-specific tumor cell functions.
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1. Introduction
The brain tumor perivascular niche (PVN), the region in the 
vicinity of microvessels, is a prime location for brain tumor 
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Traditional 2D cell cultures are incapable of replicating in 
vivo 3D environments where cancer cells reside, which may 
result in inaccurate data to evaluate drug responses.[15,16] Thus, 
there have been substantial efforts to develop 3D cell culture 
models, as well as patient-derived tumoroids, that exhibit fea-
tures closer to in vivo conditions.[17,18] These include areas of 
hypoxia, heterogeneous environment (e.g., stromal cells), dif-
ferent cell proliferation zones (quiescent vs replicating), extra-
cellular matrix (ECM) influences, soluble signal gradients, 
and differential nutrient and metabolic waste transport.[19–22] 
Existing techniques used to culture cells into 3D structures 
include scaffold-based approaches (e.g., polymeric hard scaf-
folds, biologic scaffolds, micropatterned surfaces)[23–25] and 
non-scaffold-based approaches (e.g., hanging drop microplates, 
spheroid microplates containing ultralow attachment (ULA) 
coating, and microfluidic 3D culture).[22,26,27] To date, current in 
vitro cancer models lack perfusable microvasculature, and thus, 
may not capture the essential role of microvascular niches in 
tumor progression and therapeutic response.[28–30]
Recently, perfusable microvasculature in microfluidic sys-
tems have been developed.[31–40] Several studies reported a 
spontaneous microvasculature formation via a vasculogenesis-
like process in a hydrogel loaded microfluidic chamber,[31,32] 
in which the seeding of endothelial cells in hydrogel-loaded 
microfluidic networks leads to endothelial proliferation and 
lumen formation.[33–36] Kamm et al. developed a microflu-
idic device containing 3D perfusable microvessel networks to 
investigate tumor cell intra- and extravasation.[37,38] Phan et al. 
reported that 3D microtumors/tumoroids made of colorectal, 
breast, and melanoma tumor cell lines can be revascularized 
in a perfusable diamond-shaped microchambers to study drug 
responses.[41] To our knowledge, current vascularized-tumor-
on-a-chip models have incorporated cancer cell lines as a proof-
of-concept, but it has not yet been demonstrated that such a 
platform can work as a pathophysiologically relevant system 
to evaluate the function of primary tumor cells ex vivo in a 
patient-specific manner.
We report on the first demonstration that a tissue-engineered 
microvasculature-on-a-chip system can be utilized to examine the 
function of primary patient-derived BTSCs. Live cell imaging of 
tumor cell dynamics and localization allowed for delineating the 
interaction of single brain tumor cells with the nearby microves-
sels. We found that BTSCs preferentially localize in the region 
within ≈50 µm from microvessels and that a fraction of these 
cells directly attach onto the vessels. We further validated our 
results using single-cell RNA sequencing of 10 GBM patients (26 
batches, 21 750 single cells). We found that tumor-microvessel 
colocalization was based on the genetic and pathologic subtypes 
of the tumor samples. Our GBM-microvasculature-on-a-chip 
model demonstrates the potential for ex vivo analysis of tumor 
cell functions and patient-specific GBM treatment.
2. Results and Discussion
2.1. Perfusable Endothelialized Microvasculature-on-a-Chip
Our microfluidic device (AIM Biotech) is comprised of a 
center chamber for loading a mixture of endothelial cells and 
hydrogel precursor and two lateral channels for perfusing cul-
ture medium (Figure 1a). The cell/hydrogel loading chamber 
and two lateral channels are separated by triangular microposts 
which prevent gel leaking.[42] Human umbilical vein endothe-
lial cells engineered for expression of green fluorescence 
protein (GFP-HUVECs, Angio-Proteomie) were suspended 
in a 2.5 mg mL−1 fibrin gel precursor and loaded into the 
microfluidic chamber. Premature nascent lumens developed 
in 3 d via a vasculogenesis-like self-assembly process. A con-
nected microvessel network spanning the entire chamber 
(≈1.3 mm × 8 mm) was established in 4–6 d (Figure S1a,b, 
Supporting Information) upon daily perfusion with medium. 
Previous studies showed that adding stromal cells (e.g., mes-
enchymal stem cells and lung fibroblasts) which secrete proan-
giogenic factors in the hydrogel accelerated vasculogenesis 
and expedite the formation of interconnected perusable micro-
vascular network in as little as 3 d.[43] However, because such 
stromal cells are not naturally found in the brain niche, we 
did not include them in our model. Instead, we used medium 
containing a cocktail of growth factors (vascular endothelial 
growth factor (VEGF, 50 ng mL–1), fibroblast growth factor 
(FGF, 20 ng mL−1), epidermal growth factor (EGF, 20 ng mL−1)) 
to promote in vitro microvasculature growth. Anastomosis of 
microvessels was observed at the vessel openings to medium 
flow channels, which allowed for perfusion and the establish-
ment of shear stress in the microvascular network to foster 
microvessel development and maturation.
2.2. Incorporating Primary GBM Cells in the 
Microvasculature-on-a-Chip System
To investigate the behavior of BTSCs in the microvascular envi-
ronment, we used a well-characterized, patient-derived brain 
tumor neurosphere culture, GS5 (Figure S2a,b, Supporting 
Information). Unlike U87 cells, GS5 cells are enriched for 
tumor stem-like cells and can generate highly infiltrative tumors 
in mice, mimicking human GBM histopathologically.[29,44] Com-
pared to U87-derived tumors, GS5-derived tumors more accu-
rately recapitulate the infiltrative nature of GBM in xenograft 
mouse models.[44] In addition, GS5 cells exhibit a stem-like phe-
notype with expression of multiple neurodevelopmental genes. 
As an intermediary between U87 cells, a stable cell line that loses 
many important GBM features, and primary patient-derived 
tumor cells, GS5 cells served as a reference for patient-derived 
stem-like GBM cells. GS5 cells were mixed with GFP-HUVECs 
in the hydrogel precursor at a 1:4 ratio and loaded into the 
microfluidic device to grow 3D microvasculature. Endothelial 
cells began to connect together to form networks by day 2 and 
grew into extensive microvessels by day 4 (Figure 1b). Tumor 
cells exhibited motility while the microvessels were remodeling 
until reaching a relatively stable geometry by day 6.
A whole chip scan (Figure 1c) showed the formation of inter-
connected microvessel network in day 4. After determining the 
patency of the microvessel network, finite element simulations 
were performed to determine the local flow rates (Figure 1d) 
and shear stresses in the microvessel bed. Florescent images 
were vectorized and imported into COMSOL Multiphysics 
to simulate the flow of media. With a gradient of 10 Pa, the 
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maximum shear stress experienced by microvessels was 
4.02 dyne cm−2 and the maximum flow rate in the microvessels 
was 3.21 mm s−1. The simulations revealed the heterogeneity 
that exists within the microvessels and how flow and shear 
properties influence the interaction between tumor cells and 
the adjacent vessels.
To confirm that tissue-engineered microvessels are physiolog-
ically functional and resemble native microvessels, we examined 
the formation of lumen and the presence of protein markers 
indicative of essential physiological characteristics. Confocal 
imaging showed that our microvessel network developed open 
hollow lumens as early as day 3 (Figure S1c, Supporting Infor-
mation). Immunostaining of the fixed microvessels for VE-Cad-
herin revealed the formation of endothelial cell adherens junc-
tion over a large area of the microvascular network (Figure 1d, 
left). In response to shear stress induced by medium perfusion, 
microvessels produced von Willebrand factor (vWF), a secreted 
factor that was deposited onto the inner wall of endothelia and 
polymerized to form vWF fibers that can facilitate platelet adhe-
sion (Figure 1d, right). Cross-sectional confocal imaging also 
revealed that endothelial cells secreted and deposited collagen 
IV to the basal surface of lumen, forming a 3D collagen IV 
mesh as early as day 3. This collagen layer not only stabilizes 
microvessels but also constitutes an important ECM compo-
nent of the PVN in our model (Figure 1f). This also demon-
strated endothelial cell polarization during lumen formation. In 
addition, the production of collagen IV and deposition of ECM 
are indicative of microvessel maturation.
To further evaluate the quality of microvessels, we tested the 
permeability via the perfusion of 70 kDa fluorescently labeled 
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Figure 1. Growth of BTSC-incorporated microvasculature-on-a-chip. a) Microfluidic device (250 µm in height) containing a cell/gel loading micro-
chamber (8000 µm × 1300 µm) flanked by two medium flow channels (500 µm in width). An array of triangular microposts separate the gel chamber 
and the medium flow channel, allowing for loading and confining the hydrogel precursor to the midchamber only. Scale bar: 1000 µm. b) Representative 
time course images of the microvessel formation over a period of 6 d. Scale bar: 15 µm. Green: GFP-HUVEC. c) Whole chip scan showing microvascu-
lature formation (96 h postcell in fibrin) and loading of single BTSCs (GS5). Green: GFP-HUVECs. Red: BTSCs. Scale bar: 1000 µm. d) Comsol Finite 
Element Simulation of flow velocity magnitude (mm s−1). The finite element model was constructed using the experimental whole-chip microvessel 
network in (c). e) Immunostaining of VE-cadherin and vWF to examine the formation of adherens junction and the function of tissue-engineered 
endothelial vessels at day 3. Scale Bar: 20 µm. f) Cross-sectional confocal image showing two adjacent microvessels and collagen IV deposition. Green: 
GFP-HUVECs. Red: collagen IV. g) Infusion of 70 kDa fluorescent dextran to measure impermeability of the lumen and examine microvessel opening 
to the media channel (anastomosis). Green: GFP-HUVECs. Red: Dextran. Scale Bar: 110 µm. h) Flowing fluorescent microbeads (red) (10um) through 
a microvessel network (green) that were grown for 3 d. Scale Bar: 100 µm. i) An SEM image of the microvessel. Scale Bar: 5 µm.
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dextran (Figure 1g). We used time-lapse imaging to calculate a 
permeability coefficient of (1.91 ± 0.45) × 10−6 cm s−1 (n = 4, 
at day 6), which was comparable to previously reported results 
for in vitro microvessel models.[32,43,45] This permeability coef-
ficient is higher than that in the mural/stromal cell supported 
microvessels, suggesting that microvessels made of a mono-
layer of endothelial cells are leakier in the absence of other 
vascular mural cells, such as fibroblasts and pericytes. Fur-
thermore, a suspension of 10 µm sized fluorescent polystyrene 
beads was perfused into the upper channel of a 3 d old chip. 
We observed that the beads readily traveled through the micro-
vascular network and entered the lower microchannel with 
minimal adherence to the microvessel wall (Figure 1h and 
Movie S1, Supporting Information). Finally, the microvascula-
ture hydrogel slab was retrieved, fixed, and dehydrated for scan-
ning electron microscopy (SEM) to confirm the formation of 
3D architecture of interconnected endothelial lumen network 
(Figure 1i).
2.3. Preferential Localization of BTSCs in PVN
The role of PVN in controlling BTSC fate has been reported 
in human GBM and validated with animal xenograft 
models.[4,5,46,47] Using tissue-engineered microvasculature 
models to determine whether BTSCs preferentially localize 
within the PVN, we quantified colocalization of microvessels 
and BTSCs (GS5) relative to a GBM cell line (U87). Tumor 
cells were prestained with lipophilic cell tracking dye Dil (Inv-
itrogen), mixed with GFP-HUVECs, and loaded into the micro-
fluidic chip to examine microvessel growth and tumor cell 
dynamics. After 7 d, we observed that BTSCs preferentially 
localized in the perivascular zone (Figure 2a), specifically in the 
bifurcation region of the microvessel network. In contrast, U87 
cells were overpopulated and did not colocalize (Figure 2b). 
In addition, we observed that incorporation of U87 cells led 
to fast microvessel remodeling and unstable microvessel net-
work formation, whereas GS5 cells resulted in well-connected 
microvessel network in 4–5 d. Previous in vivo studies reported 
that U87 failed to accurately model human GBM compared to 
patient-derived tumor stem cells.[30,48] Researchers character-
ized multiple GBM cell lines and showed that U87 exhibits 
high mitotic figures (as measured by Ki67) but low levels of 
neural stem cell markers, such as nestin, Sox2, and CD133.[48,49] 
Our result is concordant with previously reported studies that 
compare different cell sources for tumorigenic GBM models. 
In practice, pathologists diagnose GBM based on three golden 
standards: mitoses, microvascular proliferation, and necrosis.[50] 
Adv. Sci. 2019, 1801531
Figure 2. Quantification of tumor cell localization relative to microvessels. a) Phase and fluorescent images of microvessels with BTSC GS5. BTSCs 
were incubated with the Dil membrane dye for 40 min prior to coculture with GFP-HUVECs. BSTCs localize more preferentially to the branching 
points of the microvessel network. Scale bar: 80 µm. b) Fluorescent images of GBM cell line RFP-U87 cells loaded in a microvessel network. RFP-U87 
cells randomly distributed in the gel space and the microvessels constantly remodeled. Scale bar: 80 µm. c) Quantitative analysis of colocalization 
of GS5 versus U87 cells with the microvessels. d) Confocal images to examine colocalization of GS5 cells and microvessels. Red: GS5 cells. Green: 
HUVECs. Scale Bar: 100 µm. e) SEM image (false color) showing a BTSC on the microvessel. Scale:5 µm.
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However, it is not fully characterized how proliferative GBM 
cells migrate and distribute in the brain relative to the vascular 
system.[51] We observed that GS5-EC coculture system exhib-
ited a more connected vessel network. GS5 cells resided in the 
region near microvessels, whereas U87 showed a different local-
ization pattern in a similar device. We used ImageJ to deter-
mine the colocalization of tumor and microvessel signals in the 
same image by quantifying the Pearson’s correlation coefficient 
(see the Experimental Section). Quantitative analysis confirmed 
that patient derived BTSCs (GS5) showed a significantly higher 
Pearson’s correlation coefficient (0.44± 0.02, n = 11) than that 
of U87 cells (−0.03 ± 0.02, n = 10) (Figure 2c) 7 d after loading 
into the microchip. One popular hypothesis of tumor nutrient 
supply is that tumor cells can respond to the existing blood ves-
sels (vessel co-option).[8] As we could observe and evaluate the 
relative tumor-vessel location, our model may serve as a high-
throughput platform to test anti-vessel-co-option drug in vitro.
Scanning confocal microscopy was used to show the 
3D location of BTSCs (red) relative to microvessels (green) 
(Figure 2d). The distribution of BTSCs in this 3D hydrogel slab 
mirrored the structure of the microvessel network. We did not 
observe tumor/endothelial cell colocalization where the per-
fusable lumens did not form with U87. Furthermore, about 
30% of BTSCs appear to be fully integrated in the endothelia 
of microvessels (Figure 1c). It has been reported that brain 
tumor stem cells can differentiate into vascular cells, such as 
pericytes or endothelial cells, and contribute to tumor angio-
genesis.[52–54] We did not observe any tumor cell intravasation 
or transdifferentiation across vessel wall on our chips. We 
found that most tumor cells adhere and spread onto the sur-
face of microvessels, presumably via adhesion to collagen IV 
mesh produced by endothelial cells (Figure 1e). In contrast 
to the smooth surface of endothelialized microvessels (Figure 
S2c,d, Supporting Information), cell surfaces of BTSCs are 
very rough and decorated with extensive vesicles (Figure S2e, 
Supporting Information), suggesting their secretory activity to 
elicit a more complex cell–cell communication network in the 
PVN.[55,56] Recent studies report that secreted extracellular vesi-
cles of BTSCs contain proangiogenic factors (e.g., VEGF) that 
may contribute to vessel formation.[55,57] This may explain why 
the chip containing GS5 cells and HUVECs exhibited a more 
branched microvessel network, while the chip containing U87 
and HUVECs barely formed any perfusable vessels.
Our findings indicate the potential of a tissue-engineered 
microvasculature-on-chip system as a functional surrogate to 
examine the interaction between tumor cells and the PVN, and 
potentially as a platform for ex vivo assay of tumor cell proper-
ties. Although it is unclear where and how tumor cells decide 
to reside in the niche, we propose they are related to the signals 
associated with oxygen gradients, nutrient gradients, endothe-
lial cell-secreted factors, and interactions between BTSCs and 
ECM on the vessel surface.
2.4. Tracking Tumor Cell Migration in PVN
We observed extensive colocalization of GS5 BTSCs in the 
perivascular region 7 d after the formation of interconnected 
microvessel network (Figure 3a). However, how each cancer 
cell migrates relatively to microvessels to eventually “home” 
in the perivascular region remains unclear. To explore the 
underlying mechanisms, we utilized live cell tracking fluo-
rescence microscopy (Figure 3b) to image GS5 cells in the 
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Figure 3. Tumor cell migration in the microvasculature-on-a-chip. a) SEM image (false color) of a typical microvessel network (green) with GS5 cells 
(red). Scale: 50 µm. b) Fluorescence images of a representative region at different time points to track tumor cell migration. c) Migration trajectory 
of 13 tumor cells in the region shown in (b) for a day 3 microchip and measured over a period of 20 h. Axes unit: pixel. d) Average motility (µm h−1) 
of single tumor cells from three groups defined by the initial location of tumor cells relative to microvessels. On-Vessel (10.29 ± 7.23 µm, n = 28); 
Proximity (4.60 ± 5.11 µm h−1, n = 16); distant (5.94± 5.29 µm h−1, n = 13). ANOVA test (p = 0.0133, Kruskal-Wallis Test). e) Absolute displacement of 
single tumor cells from three groups. On-Vessel (70.71 ± 75.96 µm, n = 28); proximity (19.32 ± 38.42 µm, n = 16); distant (46.28± 59.5 µm, n = 13). 
ANOVA test (p = 0.0042, Kruskal-Wallis Test).
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microvasculature-on-a-chip device 2 d after cell seeding for 
a period of 20 h (48–68 h post-cell loading) at a rate of two 
scans per hour. We observed that most tumor cells (i.e., cell 
3 in Figure 3b) residing in the perivascular region had reduced 
migration rates and a round morphology. The cells more dis-
tant from the microvessels showed spindle-like morphology 
and extended filopodia but did not migrate over long distances. 
Surprisingly, the most migratory cells (i.e., cell 1 in Figure 3b,c) 
were located very close to or traveled along the microvessels 
(Figure S3b, Supporting Information). It is known that brain 
tumor cells utilize the microvascular tracks to invade distant 
regions of the brain. The migratory phenotype is predominately 
de-differentiated or mesenchymal, resembling the GBM mes-
enchymal subtype that often causes nonresectable disease.[58–60] 
Our result is consistent with prior in vivo studies[12] and sug-
gests that our set-up is potentially capable of differentiating 
between highly invasive tumor cells and stem-like quiescent 
tumor cells.
Next, we calculated cell motility and migration dis-
tance to determine the cell migration trajectory (Figure 3c, 
Figure S3a and Movie S3, Supporting Information). We grouped 
the cells based upon each cell’s relative distance to the nearest 
microvessel into three categories: On-Vessel (the distance to 
vessel in our fluorescence image = 0), Proximity (the distance 
to vessel < 50 um) and Distant (the distance to vessel > = 50 um 
which is considered as outside the PVN). Statistical analysis 
(one-way ANOVA) demonstrated significant differences in 
the total displacement (p = 0.0121) or motility (p = 0.0134) 
(Figure 3d,e) among these groups. Tumor cells residing in the 
PVN were mostly round but the ones outside the PVN were 
constantly extending filopodia to explore their surroundings. 
Interestingly, the lowest migratory distance cell group was not 
On-Vessel but the Proximity group. The On-Vessel group was up 
to 5x higher motility compared to Proximity group. We hypoth-
esized that the direct interaction between tumor cells and the 
collagen mesh on the vessel surface was responsible for facili-
tating tumor cell adhesion and directioning migration.
The surface marker phenotype was also measured by immu-
nostaining for nestin and Sox2, and the result confirmed that 
a significant fraction of BTSCs was perivascular. In the PVN, 
61.6% ± 2.2% (n = 3, day 7) of BTSCs were nestin-positive cells 
and 68.2 ± 4.0% positive for Sox2. The observation of tumor 
cell differential dynamics in PVN was unanticipated and dem-
onstrated the feasibility to use live cell dynamics measured in 
our device to assay the functional phenotype of single brain 
tumor cells in a physiologically relevant environment.
2.5. All Patient Samples: Colocalization of Tumor 
Cells and Microvessels
To assess interpatient heterogeneity of brain tumor cells’ PVN 
“homing” ability, we applied the same approaches to evaluate 
additional 9 patients’ BTSCs. All patient samples (Figure 4a) 
used were IDH wild-type, GBM, with differing O6-methylgua-
nine–DNA methyltransferase (MGMT) promoter methylation, 
epidermal growth factor receptor (EGFR) amplification status, 
stem-cell markers Sox2 or nestin, (Figure 4b), and ability to 
grow tumors in mice. A representative whole chip scan (sample 
GBM6, Figure 4c) showed extensive microvessel growth by 
day 4, while BTSCs largely remain isolated. The relative dis-
tance between each tumor cell and the nearest microvessel was 
measured to calculate a Pearson’s colocalization coefficient R 
value for each patient sample. The results together with GS5 
cell data in day 4 were rank ordered and plotted in Figure 4d. 
GS5 ranked highest, and other top ranked patient samples 
included GBM6, GBM24, and GBM5. The lowest colocalization 
coefficient in the group was patient GBM12, with a colocali-
zation coefficient nearly a third of that for GBM6. We noticed 
significant morphological differences in tumor cells when 
interacting with microvessels (Figure 4e). For example, the 
typical perivascular GBM5 cells wrapped around the microves-
sels and actively produced microvesicles. The morphology of 
GBM6 cells in the microvessel network resembled that of brain 
tumor microvasculature in murine.[12] Finally, we observed an 
association between colocalization and poor prognosis in the 
xenograft. For example, GBM5 and GBM6 had relatively high 
colocalization coefficients and rapid tumor growth (<100 d), 
while the four samples ranked lowest in the localization coeffi-
cient (include which samples these are) had the best prognosis 
after tumor formation in xenograft mouse models (>100 d). 
This points to a potential application of our ex vivo on-chip 
tumor cell localization assay to predict both in vivo and clinical 
outcome.
2.6. Single-Cell RNA-Seq to Correlate with Transcriptional 
Subtypes and Gene Signatures
To correlate the observed brain tumor cell behavior heteroge-
neity with the microvasculature-on-a-chip system to tumor cell 
genotype or phenotypes, we conducted single-cell 3’ mRNA 
sequencing of all ten patient samples (Table S1, Supporting 
Information) and obtained 26 027 single-cell transcriptomes 
at a depth of at least 10 000 reads per cell. To minimize the 
sequencing batch-to-batch bias, we prepared 2–3 batches of 
cDNA libraries for each patient sample for a total of 26 batches. 
The mean of transcripts (UMIs) per cell detected in each batch 
ranged from 6192 to 20174. The median of genes detected 
per cell ranged from 1740 to 3626. In total, 24 120 genes in 
21 750 cells passed the Seurat quality control filtering (see the 
Experimental Section) and were used for downstream analysis 
(Table S1, Supporting Information). The whole transcriptome of 
all single cells was used to perform differential gene expression 
and clustering analysis. The result was analyzed by both Prin-
cipal Component Analysis (PCA) (Figure S5a–c, Supporting 
Information) and t-distributed stochastic neighbor embedding 
(tSNE) (Figure 5a, Figure S5c–d, Supporting Information). 
Unsupervised tSNE clustering based on the top 1000 highly 
variable genes suggested that interpatient heterogeneity was 
stronger than the global transcriptional state of between tumor 
cells within the same sample, which was consistent with a pre-
vious report.[61]
To identify the transcriptional programs intrinsic to GBM 
cells and compare them across all ten patients such that the 
observed ex vivo behaviors in the PVN microchip model can be 
associated with molecular mechanisms, we performed the fol-
lowing informatics analysis. First, we did single-sample Gene 
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Set Enrichment Analysis (ssGSEA)[62] with the gene signatures 
previously reported[63] to quantify tumor cells expressing stem 
cell characteristics and found that most patient samples had a 
high percentage (12.05–17.49%) of stem-like cells, except for 
GBM24 (8.77%) and GBM30 (5.79%) (Table S2, Supporting 
Information). Second, we validated single tumor cell subtypes 
compared to a permutated data set (permutation = 1000) in 
ssGSEA. According to The Cancer Genome Atlas (TCGA) 
data published for human GBM, there are four major geno-
types: classical, mesenchymal, proneural, and neuronal, each 
of which has specific transcriptional signatures (684 genes in 
total).[58] However, at the single-cell level, a patient’s tumor 
could consist of multiple subtypes, with the leading subtype 
presumably defining the genotype of bulk tumor.[63] At the 
transcriptional level, a few tumor cells may be enriched for 
gene markers of two subtypes. Therefore, we defined the sub-
type of a tumor cell as the dominant gene set with p-value<0.2 
(Table S3, Supporting Information). Recent studies suggested 
the removal of the neuronal subtype due to its overlap with 
the proneural subtype and suboptimum identification using 
current gene signatures.[62,63] In order to further visualize the 
lineage relationship between tumor cells in each sample, we 
applied a pseudotime differentiation trajectory method to ana-
lyze all single cells using the gene sets associated with three 
major subtypes—classical, mesenchymal, and proneural. We 
then reconstructed the pseudotime lineage relationships with 
three subtype markers (555 genes) using semi-supervised 
analysis in Monocle package.[64,65] The resulting plot had three 
major branches and three major nodes connecting them with 
two minor branches (Figure 5b). The differential gene expres-
sion between branches was shown in Figure S6 (Supporting 
Information). Next, we investigated whether tumor/microvessel 
colocalization (Figure 4d) correlated with tumor cell hetero-
geneity and subtype. We found that the top three highly colo-
calized tumor samples (GS5, GBM6, and GBM24) shared a 
similar cellular trajectory, in sharp contrast with the graph of 
the three least colocalized tumor samples (GBM12, GBM1, and 
GBM16) (Figure 5c), indicating a strong correlation between 
tumor genomic subtypes and ex vivo tumor cell dynamics in 
the microvasculature-on-a-chip system.
Linear regression analysis was performed to compare the 
percentage of stem-like, classical, mesenchymal, or proneural 
Adv. Sci. 2019, 1801531
Figure 4. All patient samples: tumor cell localization relative to microvessels. a) Patient information table. All GBM samples are IDH wild-type. M, 
MGMT promoter methylated; UM, MGMT promoter not methylated; NT, not tested. b) Immunostaining of nestin and Sox2. Scale: 30 µm. c) Whole 
chip scan of GBM6 in the microvasculature chip at Day 4. Scale: 700 µm. Red: GBM6 cells. Green: HUVECs. d) Colocalization coefficient of tumor 
cells and microvessels measured for all patient samples. e) Representative images of patient cells in the microvasculature chip. Red: GBM cells. Green: 
HUVECs. Scale: 10 µm.
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GBM cells to the colocalization coefficient (Figure 5d). Although 
none of them reached statistical significance, we observed a 
slightly positive colocalization with the percentages of stem-
like, mesenchymal, and proneurnal cells, but not classical cells. 
This finding is in agreement with previous reports,[46,66] which 
studied the role of the PVN in both stem-like cell fate main-
tenance and vascular track invasion and found mesenchymal 
cells to be the most invasive subtype. The BTSC PVN model 
was primarily validated with the proneural subtype,[67,68] but 
not the classical subtype, which has high probability of EGFR 
amplification and features enhanced cell proliferation and 
tumor growth. However, the entire panel of GBM subtype 
genes (684 genes) did not result in a statistically significant 
colocalization correlation. Furthermore, we examined specific 
gene markers with these panels but that were associated more 
with pro-angiogenesis and the interaction with endothelium 
(Figure S7, Supporting Information). Based on a multivariate 
linear mixed model with patient level effect adjusted, we tested 
if the average gene expression level of marker genes related to 
the colocalization coefficient. We found four genes (PDGFRA, 
C1GALT1, THY1, and MKI67) were significantly associated 
with the colocalization coefficient (Figure 5e, Table S4, Sup-
porting Information). Platelet-derived growth factor receptor 
alpha (PDGFRA), one of the most distinct signature genes for 
proneural GBM, was found to be expressed highly in the top 
three ranked tumor cells. This finding further supports our 
hypothesis that the “homing” of BTSCs in the PVN is well dem-
onstrated in proneural models but not others.[67–69] Endothelial 
cells in the vessels usually recruit pericytes or mescenchymal 
cells via PDGF signaling towards vessel maturation.[70] We pro-
pose that tumor cells with a high expression level of PDGFRA 
respond better to PDGF secreted by endothelial cells, and thus 
show a high vessel colocalization ratio. Although PDGF and 
PDGFRA are coexpressed in GBM, we found that amplified 
expression of PDGFRA, not PDGF nor PDGFRB, correlated 
with tumor cell-vessel colocalization. Previous clinical trials 
Adv. Sci. 2019, 1801531
Figure 5. Single-cell RNA-seq correlates on-chip colocalization to transcriptional signatures/subtypes. a) tSNE plot of single cell RNA-seq data from 
all patient samples. b) Single-cell pseudotime lineage trajectory obtained by semisupervised clustering of subtype-specific gene panel using Monocle. 
c) Representative images of tumor cells in microvasculature and the matched Monocle plots for top three and bottom three colocalization coefficient 
samples (Day 4–7). Scale bar: 200 µm. d) The linear regression model showing the percentage of GBM subtype in each sample in correlation with 
the colocalization R value. e) The multivariate linear model showing the predictor variables (average gene expression of PDGFRA, C1GALT1, THY1, 
and MKI67) as a combined transcriptional signature that correlates with colocalization. f) Relative gene expression of angiogenesis (PDGFRA, SCG2), 
proliferation (MKI67), and housekeeping marker (RPLP0) in single cells from all patient samples.
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using PDGF receptor antagonists have been disappointing.[71,72] 
This could be due to the interpatient and/or intrapatient het-
erogeneity of GBM cells, which is consistent with the mRNA 
data in our study (Figure S5d, Supporting Information). Recent 
advances in genetic profiling suggests that combination therapy 
targeting multiple receptor tyrosine kinases (RTKs) including 
PDGFRA, EGFR, and MET could provide better efficacy.[73,74] 
SCG2, a gene associated with secretory function, was found to 
negatively correlate with colocalization, except GBM5, which 
was confirmed as an active extracellular vesicle producer 
(Figure 4e). GBM30 was found to express low levels of both 
PDGFRA and SCG2, but showed the highest proliferation and 
tumor growth capability in mouse xenografts. VEGFA, one of 
the most important proangiogenic factors, did not show sig-
nificant differences in most patient samples and no correlation 
with colocalization coefficients.
These results suggest that ex vivo behaviors of BTSCs in a 
3D microvasculature model can recapitulate pathophysiological 
characteristics, as shown by our model of the PVN. Addition-
ally, the ability to “home” to the PVN of single tumor cells can 
be associated with transcriptional subtype and correlates with 
interpatient heterogeneity. This is the first demonstration that 
a tissue-engineered 3D microvasculature system can provide a 
functional niche to assay the dynamics of primary tumor cells 
derived from patients, opening a new direction for organ-on-a-
chip applications.
3. Experimental Section
Cell Culture: Primary culture of HUVECs were purchased from Yale 
Vascular Biology and Therapeutics Core. GFP-HUVECs were commercially 
obtained (Angio-Proteomie) and cultured in endothelial growth medium 
EGM-2 (Lonza) with full supplements. HUVECs and GFP-HUVECs 
between passage 2 and 6 were used in all experiments. No significant 
difference between HUVECs and GFP-HUVECs in vessel formation 
ability was observed. Red fluorescent human GBM cells (RFP-U87) 
and patient-derived glioma stem-like cells (GS5) were provided by 
Prof. Jiangbing Zhou’s lab at Yale University. RFP-U87 were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS). All GBM specimens were provided by Yale 
Neuropathology Service. Fresh patient-derived GBM cells were isolated 
and cultured from GBM patient surgical specimens with approval 
from the Institutional Review Board at Yale-New Haven Hospital. 
Extensively rinsed tumor specimens were finely minced and placed in 
DMEM/F-12 medium (Gibco) with 25 unit mL−1 Papain (Worthington 
Biochemical Corp). A series of mechanical dissociations was used to 
obtain a single-cell suspension. Resuspended cells were cultured in 
neural basal medium supplemented with B27 (Gibco), FGF (20 ng mL−1, 
Peprotech), and EGF (20 ng mL−1, Peprotech). Brain tumor-derived 
neurospheres were evident as early as one week after plating.
Chip Loading and Maintenance: Microvessels formed by HUVECs were 
cocultured with glioma cells in a stack of fibrin gel in the 3D cell culture 
chips (AIM Biotech). The chip, adapted from Prof. Roger Kamm’s 
design, consisted of three parallel channels: one central cell-containing 
gel loading channel and two lateral medium flow channels.[75] Endothelial 
cells were seeded in the fibrin gel by introducing HUVECs (2 × 106 
cells mL−1) and GBM cells (0.5 × 106 cells mL−1) in the 2.5 mg mL−1 
fibrinogen (Sigma) dissolved in serum-free neural basal medium. 
Thrombin (5 U per 10 mg fibrinogen, Sigma) was then added to convert 
the soluble fibrinogen into insoluble fibrin strands. Immediately after 
gentle mixing, the gel (≈10 µL) was pipetted into the gel-loading channel 
of 3D cell culture chips. The samples were placed in a humidified 5% 
CO2 37 °C incubator for 40 min, to allow the fibrin to polymerize. 50% 
EGM-2 media and 50% neural basal medium supplemented with B27, 
VEGF (50 ng mL−1), EGF (20 ng mL−1), and FGF (20 ng mL−1) was 
then added to the two lateral flow channels. The gravity-driven flow was 
introduced by adding 50 µL of medium into two connected ports of the 
same channel and 70 µL into the opposite two connected ports. This 
differential volume created a transient flow across the porous fibrin gel 
and the anastomotic microvessels in the chip. Media was changed every 
12 h for a period of up to 2 weeks.
Immunofluorescent Staining and Imaging: For live cell tacking, brain 
tumor stem-like cells GS5 were incubated with Dil cell membrane dye 
(1:200, Invitrogen) for 40 min in a humidified 37 °C incubator. For 
immunofluorescent staining, devices were fixed by 4% paraformaldehyde 
(ChemCruz) for 20 min at room temperature. Primary antibodies were 
used at 1:100 overnight at 4 °C and secondary antibodies were used at 
1:1000 for 1 h at room temperature (Table S6, Supporting Information). 
The 3D microvessels were imaged using a confocal microscope (Leica 
DMi8) and deconvoluted by Hyugens Professional software (Scientific 
Volume Imaging). Unless otherwise stated, all other images were taken 
with Nikon Eclipse Ti-S microscope and processed with NIS-Elements 
software (Version 4.20, Nikon Instruments).
Single Cell 3’ mRNA Sequencing: Our approach for high-throughput 
single cell mRNA sequencing was based on a closed microwell array 
chip developed in our lab.[76] Microwell arrays were used as the platform 
for coisolating single cells and uniquely barcoded mRNA capture 
beads for single cell mRNA capture following lysis. The dimensions of 
microwells are dictated by the size of mRNA capture beads (≈35 µm); 
and chosen as ≈45–55 µm in diameter and ≈50 µm in height to ensure 
accommodation of only a single bead as well as most mammalian cell 
types. This choice of dimensions also facilitates straightforward removal 
of beads after mRNA capture either by purging (for closed-environment 
cell seeding) or centrifugation (for open-surface cell seeding) after 
inverting the devices. The throughput of the microwell arrays is up to 
70 000 wells to be able to sequence ≈1000–5000 cells in a single run 
where the arrays are loaded with a well occupancy rate of 5–10% to 
minimize dual occupancy (cell duplets).
Master wafers for microwell arrays were fabricated using SU-8 
negative resist. A single layer of resist (SU-8 2035, MicroChem) was 
spun at 2200–2400 rpm for 30 s to yield feature heights of ≈50 µm. The 
wafers were then exposed to ultraviolet light through a transparency 
mask (CAD/Art Services) to pattern microwells. After developing and 
baking, wafers were hard baked at 150 °C for 30 min, and silanized 
for 2 h in a vacuum chamber saturated with Trichloromethylsilane 
(Sigma-Aldrich). Fabrication of microfluidic channels followed a similar 
fabrication procedure using SU-8 2075 where channel height was set to 
≈120 µm (1700–1800 rpm for 30 s).
Devices were made by casting polydimethylsiloxane (PDMS, Sylgard 
184, Dow Corning) over the master wafers followed by degassing and 
curing at 80 °C for 6–8 h. Both microwell array and microfluidic channel 
device were set to a final height of 3–4 mm. After curing, PDMS was 
peeled off, and devices were cut to proper sizes to fit on a glass slide. 
For microfluidic channels, holes for fluidic connections were punctured 
using a biopsy punch (Miltex, 1.5 mm). Microwell arrays were first 
plasma-bonded to microfluidic channel and then to a glass slide.
For single cell RNA-seq experiments, the patient-derived GBM 
neurospheres were cultured for 3–5 weeks in serum-free media as 
described above and then gently pipetted with a 200ul pipette tip to 
dissociate into single cells. Dissociated single cells and mRNA capture 
beads were then inputted into the microwell chip sequentially using 
a pipette and allowed to settle into wells by gravity using syringe-
pump driven flow. Freeze-thaw lysis buffer was introduced into the 
microchannel followed by fluorinated oil (Fluorinert FC-40) to seal each 
microwell to prevent cross-contamination. Cell lysis was achieved using 
three freeze-thaw cycles, and cell lysate and beads were incubated at 
room temperature for 60 min for mRNA capture on beads. Following 
incubation, beads were removed from the microfluidic device by flushing 
the beads out into an Eppendorf tube. Following bead removal, reverse 
transcription and library construction were performed as previously 
described.[76]
Adv. Sci. 2019, 1801531
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Fixation and Dehydration of Brain Tumor Stem Cells Near Microvessels 
for Scanning Electron Microscopy: For the field emission scanning 
electron microscopy (FE-SEM) observation, the plastic chip was fixed 
and dehydrated with cell-containing gel 6–10 d postembedding. The 
transparent gas-permeable film at the bottom of AIM 3D cell culture 
chip was carefully delaminated by a tweezer. Fixation and dehydration 
for SEM preparation was conducted using the same process described 
in our previous paper.[77] In brief, the samples were first fixed with 4% 
paraformaldehyde for 20 min at room temperature and then 2.5% 
glutaraldehyde for 1 h at 4 °C. Secondary fixing was followed with 1% 
osmium tetroxide for 1 h at 4 °C. Then, fixed cells were dehydrated by 
using a grade series of ethanol concentrations (25%, 50%, 75%, and 
95%) and followed by final dehydration with 100% ethanol twice for 
10 min at 4 °C. Subsequently, dehydrated samples were frozen for 3 h 
at −80 °C, and then air dried for 24 h in a vacuum desiccator. To observe 
the microfeatures using FE-SEM, the samples were sputter-coated with 
a layer of iridium (≈12 nm) as a conductive surface layer. An FE-SEM 
(SU-70, Hitachi) was used for observation.
Data Analysis: Tumor Morphology and Localization Analysis: The 
morphology of BTSCs were analyzed with NIS-Elements software 
and ImageJ. From day 4 to day 6, representative images of each 
patient BTSCs with GFP-HUVECs were selected for analysis. Each raw 
image of membrane-labeled fluorescent BTSCs (Data type: TIFF, size: 
1392 × 1940 pixels2, about 0.12 mm2) was binarized by the auto threshold 
tool and manually segmented through freehand tool. Colocalization 
correlation of tumor cells and endothelial cells was evaluated by the 
Pearson’s correlation coefficient by the colocalization test tool in 
Fiji software.[78,79] The coefficient ranges from −1 to 1: +1 for perfect 
correlation, 0 for no correlation, and −1 for perfect anticorrelation.
Permeability Test: The permeability of microvessels was examined via 
perfusing 70kDa-Cy5 dextran (Invitrogen) into the microvessel network. 
It was measured based on four regions in two independent chips. To 
avoid border effect, these four regions were mostly in the central region 
of the gel channel. Dextran was diluted in EGM-2 medium at a final 
concentration of 25 µg mL−1. All the loading ports were filled with 40 µL 
medium prior to the test, then 30 µL of dextran was added into one 
port. A time lapse sequence of the fluorescence intensity was recorded 
for 30 min, at an interval of 30 s. Once the intravascular fluorescence 
intensity established equilibrium, typically 5–10 min post injection, 
permeability was quantified using fluorescence images obtained every 
30 s for 2 min. The method described in previous studies was followed 
to calculate the permeability using the values of average diameter of the 
lumen (d), fluorescence intensity at the intravascular region (I0), and 
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Cell Motility: GFP-HUVECs and Dil-stained patient-derived GS5 
cells in fibrin gel were seeded in the AIM chip and allowed to grow for 
48 h. After premature vessel formation, the plate holder of the chip 
was mounted on a Nikon Eclipse Ti-S microscope with a motorized 
stage (Prior Scientific) and an environment control incubation 
chamber (Okolab) to maintain 37 °C with 5% CO2. Phase contrast and 
fluorescent images were recorded every 30 min for 20 h using a CCD 
camera (ANDOR) with a low magnification 4X Fluor objective. Each 
single cell was manually labeled in the continuous frames for 20 h. Cell 
motility parameters were assessed via tracking of single tumor cells 
(n = 3, ≈20 cells per cropped region per trial) using Fiji. Motility was 
defined as the distance traveled in a unit time. Cellular displacement was 
calculated using the corresponding x and y coordinates at initial time t0 
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Finite Element Simulation (FEM) Analysis: COMSOL Multiphysics 
(Version 5.0, COMSOL) software was used to perform finite element 
analysis on the AIM Biotech microfluidic device set up. 2D fluorescent 
images of microvessels formed in the AIM Biotech devices were 
created in COMSOL and simulations were performed to mimic 
the microenvironment the vessels and cells were experiencing. A whole 
chip scan image of GBM6 in the microenvironment of green fluorescent 
HUVEC microvessels (Day 4) was first bianarized using ImageJ. Then, 
using WinTopo Raster to Vector Conversion Software (v1.76, SoftSoft 
Ltd.), the black and white BMP images were converted to vectorized 
images which could be imported into COMSOL. To successfully 
vectorize the images in WinTopo, various image processing techniques 
such as erosion, despeckle, and prune were used to create an 
acceptable image that could be processed using edge detection. The 
vector file was then imported into COMSOL and used to reconstruct the 
microvessel environment. The free and porous flow module was applied 
to simulate for media and fibrin respectively. Media flow with a density 
of 1020 kg m−3 and viscosity of 0.8 cP was governed by the Navier–
Stokes and continuity equations for laminar flow.[81,82] The fibrin was 
modeled as a porous matrix with a porosity of 0.99 and a permeability 
of 1.5 × 10−13 m2 and was simulated using the Brinkman equation.[83] 
The geometry was scaled and meshed in COMSOL with a minimum 
element size of 0.09 mm and a maximum element size of 0.6 mm. For 
initial conditions, a pressure gradient of 10 Pa from the top to bottom 
channels was used to represent a column height difference of 1 mm. 
In the simulation, two inlets were on top and two outlets were on the 
bottom by assumption. Hydrostatic pressure from a column height of 
1 mm representing 10 Pa was used as the inlet pressure while the outlet 
pressure was set to 0 Pa.
Single Cell mRNA Sequencing Analysis: In total, we sequenced 26 027 
single cells by using 75 bp pair-end reads on a HiSeq2500 instrument 
(Illumina) in HighOutput Mode V4. Raw reads were preprocessed for 
cell barcodes and UMIs, and then aligned to the human genome(hg19) 
using STAR v2.5.2b as described in Dropseq method.[84] Digital 
expression matrix was generated for the cells with over 10 000 reads per 
cell.
The Seurat package (V2.3.0) in R (V3.4.1) was applied to identify 
differentially expressed genes among 26 027 single cells from nine 
different GBM patients and one GBM cell reference (GS5).[85] Cells 
were considered in the analysis only if they met the following quality 
control criteria: 1) expression of more than 1000 genes and fewer than 
5000 genes; 2) low expression of mitochondrial genes (<10% of total 
counts in a cell). After filtering, 24 120 genes in 21 750 cells were left 
for clustering analysis. Genes that were differentially expressed in 
each cluster were identified using the Seurat function FindMarkers, 
which returned the gene names, average log fold-change, and adjusted 
p-value for genes enriched in each cluster. Unsupervised clustering in 
principal component analysis (PCA) was performed with 30 statistically 
significant principal components that were identified from the top 1000 
highly variable genes from all the samples. We then projected single 
cells onto a two-dimensional map using tSNE to discover interpatient 
heterogeneity.
The Monocle package (V2.6.4) was used to plot single cell 
pseudotime trajectories to discover the behavioral similarity and 
transitions.[64,65] We use the proneural, mesenchymal, and classical 
subtype genes identified before to perform the semi-supervised 
analysis.[58] Monocle looked for variable genes and augmented the 
markers when construct the clustering and ordering of the cells. 
DDRTree algorithm was used to visualize the pseudotime trajectory 
in the reduced dimensional space. Plot_genes_branched_heatmap 
module was applied to plot out the genes (qval<1e-300) that had 
similar expression profile on a branch.
Statistics: Results were shown as mean ± standard deviation. Student 
t-test was used to assess the comparisons between the groups in 
Figure 2. Statistical analysis (one-way ANOVA) demonstrated significant 
difference among three groups of these measurements in Figure 3d,e. 
Statistical significance was assumed for p < 0.05, unless otherwise 
specified. In Figure 5e, a multivariate linear model in JMP (Version 13.0) 
was performed to show that four predictor variables (gene expression 
of PDGFRA, C1GALT1, THY1, and MKI67) correlate with colocalization 
coefficient. The p-values (Table S4, Supporting Information) were 
calculated based on a multivariate linear mixed model with patient level 
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effect adjusted in R(V3.4.1). Akaike information criterion (AIC) and 
Bayesian information criterion (BIC) were utilized for model selection. 
All tests were performed with Prism (Version 7.0, GraphPad Software), 
JMP (Version 13.0, SAS Institute), or R (V3.4.1).
Sequencing Data Availability: The single-cell RNA-seq data is available 
in the Gene Expression Omnibus (GEO) under accession GSE125587.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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